公开(公告)号：WO2023086812A1

公开(公告)日：2023-05-19

申请号：PCT/US2022/079530

申请日：2022-11-09

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： SHEN, Yang ,  WANG, Bei ,  AVVARU, Naga Suhasini ,  LIN, Chia-Yang ,  MURPHY, Andrew ,  HERMANN, Aynur ,  KIM, Jee H.

IPC: C07K16/28 ,  C07K14/705

Abstract: The present disclosure relates to molecules capable of binding to both CD20 and PD1, as well as pharmaceutical compositions comprising such molecules and methods of use thereof.

公开(公告)号：WO2017015472A1

公开(公告)日：2017-01-26

申请号：PCT/US2016/043360

申请日：2016-07-21

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： DUNN, Michael ,  MORTON, Lori C. ,  RAY, Yonaton ,  KIM, Jee H.

IPC: C07K16/26 ,  A61K39/00

CPC classification number: C07K16/26 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present invention provides monoclonal antigen-binding proteins that bind to the cardiac glycoside marinobufagenin (MBG), and methods of use. In various embodiments of the invention, the antigen-binding proteins are fully human antigen-binding proteins that bind to MBG. In some embodiments, the antigen-binding proteins of the invention are useful for inhibiting or neutralizing MBG activity, thus providing a means of treating or preventing a MBG-associated disease or disorder selected from the group consisting of hypertension, myocardial fibrosis, uremic cardiomyopathy, heart failure, myocardial infarction, renal failure, renal fibrosis and pre-eclampsia.

Abstract translation: 本发明提供了结合强心苷甙蛋白原基因（MBG）的单克隆抗原结合蛋白及其使用方法。 在本发明的各种实施方案中，抗原结合蛋白是与MBG结合的完全人抗原结合蛋白。 在一些实施方案中，本发明的抗原结合蛋白可用于抑制或中和MBG活性，从而提供治疗或预防选自以下的MBG相关疾病或病症的方法：高血压，心肌纤维化，尿毒症性心肌病， 心力衰竭，心肌梗塞，肾衰竭，肾纤维化和先兆子痫。

公开(公告)号：WO2015077491A1

公开(公告)日：2015-05-28

申请号：PCT/US2014/066687

申请日：2014-11-20

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： STEVIS, Panayiotis ,  GROMADA, Jesper ,  MURPHY, Andrew J. ,  RAY, Yonaton ,  KIM, Jee H. ,  LOBOV, Ivan B.

IPC: C07K16/28

CPC classification number: C07K16/28 ,  A61K38/00 ,  A61K39/3955 ,  A61K47/64 ,  A61P9/08 ,  A61P9/10 ,  C07K14/47 ,  C07K14/705 ,  C07K14/72 ,  C07K16/2869 ,  C07K16/46 ,  C07K19/00 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30

Abstract: The present invention provides apelin receptor (APLNR) modulators that bind to APLNR and methods of using the same. The invention includes APLNR modulators such as antibodies, or antigen-binding fragments thereof, that inhibit or attenuate APLNR-mediated signaling. The invention includes APLNR modulators such as antibodies, or antibody fusion proteins thereof, that activate APLNR-mediated signaling. According to certain embodiments of the invention, the antibodies or antigen-binding fragments or antibody fusion proteins are fully human antibodies that bind to human APLNR with high affinity. The APLNR modulators of the invention are useful for the treatment of diseases and disorders associated with APLNR signaling and/or APLNR cellular expression, such as cardiovascular diseases, angiogenesis diseases, metabolic diseases and fibrotic diseases.

Abstract translation: 本发明提供了结合APLNR的apelin受体（APLNR）调节剂及其使用方法。 本发明包括抑制或减弱APLNR介导的信号传导的APLNR调节剂，例如抗体或其抗原结合片段。 本发明包括激活APLNR介导的信号传导的APLNR调节剂，例如抗体或其抗体融合蛋白。 根据本发明的某些实施方案，抗体或抗原结合片段或抗体融合蛋白是以高亲和力结合人APLNR的完全人抗体。 本发明的APLNR调节剂可用于治疗与APLNR信号传导和/或APLNR细胞表达相关的疾病和病症，例如心血管疾病，血管发生疾病，代谢疾病和纤维化疾病。